Problem Heart failure (Stage III or IV)
Format Double-blinded multi-center RCT
Treatment Bisoprolol
Control Placebo
Population 2647 patients
Inclusion criteria Aged 18–80 years
Left ventricular ejection fraction <35% NYHA class III or IV heart failure
Receiving standard therapy (diuretic plus ACE inhibitor/other vasodilator)
Exclusion criteria .
Follow-up Median 1.3 years
Primary endpoint All-cause mortality.
Secondary endpoint(s) Secondary endpoints were all-cause hospital admissions, cardiovascular mortality, cardiovascular mortality and cardiovascular hospital admissions, a composite endpoint, and permanent premature treatment withdrawals.
Details -
Brief summary: Bisoprolol improved mortality in NYHA 3-4
PAPER: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Date 2 Jan 1999
Journal Lancet. 1999 Jan 2;353(9146):9-13.
Information Significantly reduced:
-All-cause mortality
-All-cause hospitalisations